Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Case Report

Intrapancreatic Accessory Spleen Diagnosed by Size Reduction after Immunosuppressive Therapy: A Case Report

Author(s): Turgut Tursem Tokmak*, Mahmut Burak Lacin and Humeyra Gencer

Volume 20, 2024

Published on: 08 September, 2023

Article ID: e150823219727 Pages: 5

DOI: 10.2174/1573405620666230815142649

open_access

Abstract

Background: Intrapancreatic accessory spleen (IPAS) is a congenital entity that can be confused with malignant distal pancreatic masses. Radiologic imaging and radionuclide imaging have an important place in the diagnosis of IPAS.

Case Report: Blood tests were performed on a 36-year-old female patient who presented with tachypnea, tachycardia, pain in the joints, and pain in the left abdominal quadrant. Laboratory test results were as follows: hemoglobin value 6.0 mg/dl, sedimentation 120, aspartate transaminase (AST) 150U/L, and alanine transaminase level (ALT) 110U/ L. Additional laboratory tests and ultrasonography were performed. The anti-doublestranded DNA (dsDNA) level was 800 IU/ml. C3 and C4 values were both 0.64 IU/ml, with anti-Ro-52 +++(three positive) and anti-Ro-60 ++ (two positive). A clinical diagnosis of systemic lupus erythematosus (SLE) was made. Ultrasonography and dynamic contrast-enhanced upper abdominal MRI showed lesions suggestive of multiple hemangiomas in the liver and a 29x18 mm lesion in the tail of the pancreas with a similar appearance as the spleen. SLE treatment was started. Scintigraphy was recommended for the diagnosis of IPAS. Scintigraphy was performed in the third week of the treatment. Uptake was not observed. In the second month of the treatment, a control upper abdominal MRI was performed, and a decrease in the size of the lesion was observed.

Conclusion: IPAS can be confused with pancreatic masses. Lack of uptake in scintigraphy may be due to treatment protocols that produce low phagocytic activity. If radiological imaging findings are compatible, a reduction in lesion size after immunosuppressive therapy can be accepted as evidence for the diagnosis of IPAS.

Keywords: Intrapancreatic spleen, Lupus erythematosus, Magnetic resonance imaging, Pancreatic neoplasms, Case report, Immunosuppressive therapy.

[1]
Mortelé KJ, Mortelé B, Silverman SG. CT features of the accessory spleen. AJR Am J Roentgenol 2004; 183(6): 1653-7.
[http://dx.doi.org/10.2214/ajr.183.6.01831653] [PMID: 15547205]
[2]
Mohammadi S, Hedjazi A, Sajjadian M, Ghrobi N, Moghadam M, Mohammadi M. Accessory spleen in the splenic hilum: A cadaveric study with clinical significance. Med Arh 2016; 70(5): 389-91.
[http://dx.doi.org/10.5455/medarh.2016.70.389-391] [PMID: 27994303]
[3]
Yadav SP, Kotak SD, Kumar S, Pujari VS, Chandrasekaran A. Intrapancreatic accessory spleen: An imaging enigma. Indian J Radiol Imaging 2020; 30(3): 392-4.
[http://dx.doi.org/10.4103/ijri.IJRI_407_20] [PMID: 33273778]
[4]
Uchiyama S, Chijiiwa K, Hiyoshi M, et al. Intrapancreatic accessory spleen mimicking endocrine tumor of the pancreas: case report and review of the literature. J Gastrointest Surg 2008; 12(8): 1471-3.
[http://dx.doi.org/10.1007/s11605-007-0325-6] [PMID: 17929107]
[5]
Spencer LA, Spizarny DL, Williams TR. Imaging features of intrapancreatic accessory spleen. Br J Radiol 2010; 83(992): 668-73.
[http://dx.doi.org/10.1259/bjr/20308976] [PMID: 19690077]
[6]
Kim SH, Lee JM, Han JK, et al. Intrapancreatic accessory spleen: Findings on MR Imaging, CT, US and scintigraphy, and the pathologic analysis. Korean J Radiol 2008; 9(2): 162-74.
[http://dx.doi.org/10.3348/kjr.2008.9.2.162] [PMID: 18385564]
[7]
Tatekawa Y. An intrapancreatic accessory spleen presenting as a rapidly growing pancreatic mass after splenectomy in a patient with hereditary spherocytosis: a case report and literature review. J Surg Case Rep 2018; 2018(2): rjy029.
[http://dx.doi.org/10.1093/jscr/rjy029] [PMID: 29492255]
[8]
Kurashima Y, Ohno K, Hase R, et al. A case of laparoscopic resection of the accessory spleen for the recurrence of hereditary spherocytosis 17 years after splenectomy (Abstract in English). Nihon Shokaki Geka Gakkai Zasshi 2010; 43(10): 1042-7.
[http://dx.doi.org/10.5833/jjgs.43.1042]
[9]
AlShammari A, Kalagi D, Hijji T, Aburahmah M. Laparoscopic intrapancreatic accessory splenectomy: A case report of recurrent immune thrombocytopenia in a 33 years old male patient after 6 years of splenectomy. Int J Surg Case Rep 2019; 60: 168-70.
[http://dx.doi.org/10.1016/j.ijscr.2019.06.021] [PMID: 31229770]
[10]
Li BQ, Xu XQ, Guo JC. Intrapancreatic accessory spleen: A diagnostic dilemma. HPB 2018; 20(11): 1004-11.
[http://dx.doi.org/10.1016/j.hpb.2018.04.004] [PMID: 29843985]
[11]
Ding Q, Ren Z, Wang J, et al. Intrapancreatic accessory spleen: Evaluation with CT and MRI. Exp Ther Med 2018; 16(4): 3623-31.
[http://dx.doi.org/10.3892/etm.2018.6613] [PMID: 30250526]
[12]
Lin X, Xu L, Wu A, Guo C, Chen X, Wang Z. Differentiation of intrapancreatic accessory spleen from small hypervascular neuroendocrine tumor of the pancreas: Textural analysis on contrast-enhanced computed tomography. Acta Radiol 2019; 60(5): 553-60.
[http://dx.doi.org/10.1177/0284185118788895] [PMID: 30086651]
[13]
Arkadopoulos N, Athanasopoulos P, Stafyla V, et al. Intrapancreatic accessory spleen issues: Diagnostic and therapeutic challenges. JOP 2009; 10(4): 400-5.
[PMID: 19581743]
[14]
Kim SH, Lee JM, Han JK, et al. MDCT and superparamagnetic iron oxide (SPIO)-enhanced MR findings of intrapancreatic accessory spleen in seven patients. Eur Radiol 2006; 16(9): 1887-97.
[http://dx.doi.org/10.1007/s00330-006-0193-6] [PMID: 16547707]
[15]
Zurek Munk-Madsen M, Zakarian K, Sandor Oturai P, et al. Intrapancreatic accessory spleen mimicking malignant tumor: Three case reports. Acta Radiol Open 2019; 8(6): 2058460119859347.
[http://dx.doi.org/10.1177/2058460119859347] [PMID: 31285851]
[16]
Ekmekçi Ş, Diz-Küçükkaya R, Türkmen C, Adalet I. Selective spleen scintigraphy in the evaluation of accessory spleen/splenosis in splenectomized/nonsplenectomized patients and the contribution of spect imaging. Mol Imaging Radionucl Ther 2015; 24(1): 1-7.
[http://dx.doi.org/10.4274/mirt.40085] [PMID: 25800591]
[17]
Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008; 19(10): 1727-33.
[http://dx.doi.org/10.1093/annonc/mdn351] [PMID: 18515795]
[18]
Guo W, Han W, Liu J, et al. Intrapancreatic accessory spleen: A case report and review of the literature. World J Gastroenterol 2009; 15(9): 1141-3.
[http://dx.doi.org/10.3748/wjg.15.1141] [PMID: 19266611]
[19]
Harris GN, Kase DJ, Bradnock H, Mckinley MJ. Accessory spleen causing a mass in the tail of the pancreas: MR imaging findings. AJR Am J Roentgenol 1994; 163(5): 1120-1.
[http://dx.doi.org/10.2214/ajr.163.5.7976887] [PMID: 7976887]

© 2024 Bentham Science Publishers | Privacy Policy